Specific binding agents to hepatocyte growth factor

A method for treating cancer in a patient, the method comprising administering an antibody that binds human hepatocyte growth factor (HGF), wherein the antibody is selected from the group consisting of:

• an antibody comprising a light chain comprising SEQ ID NOs:
• 60, 70, and 80, and a heavy chain comprising SEQ ID NOs:
• 90, 100 and 110;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 61, 71, and 81, and a heavy chain comprising SEQ ID NOs:
• 91, 101, and 111;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 62, 72, and 82, and a heavy chain comprising SEQ ID NOs:
• 92, 102, and 112;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 63, 73, and 83, and a heavy chain comprising SEQ ID NOs:
• 93, 103, and 113;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 64, 74, and 84, and a heavy chain comprising SEQ ID NOs:
• 94, 104, and 114;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 65, 75, and 85, and a heavy chain comprising SEQ ID NOs:
• 95, 105, and 115;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 66, 76, and 86, and a heavy chain comprising SEQ ID NOs:
• 96, 106, and 116;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 67, 77, and 87, and a heavy chain comprising SEQ ID NOs:
• 97, 107, and 117;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 68, 78, and 88, and a heavy chain comprising SEQ ID NOs:
• 98, 108, and 118;
• and
• an antibody comprising a light chain comprising SEQ ID NOs:
• 69, 79, and 89, and a heavy chain comprising SEQ ID NOs:
• 99, 109, and 119.

A method of treating a solid tumor in a patient, the method comprising administering an antibody that binds human hepatocyte growth factor (HGF), wherein the antibody is selected from the group consisting of:

• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:24 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 25 from residue 20 to residue 141;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:26 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 27 from residue 20 to residue 137;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:28 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 29 from residue 20 to residue 139;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:30 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 31 from residue 20 to residue 148;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:32 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 33 from residue 20 to residue 139;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:34 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 35 from residue 20 to residue 144;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:36 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 37 from residue 20 to residue 142;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:38 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 39 from residue 20 to residue 139;
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:40 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 41 from residue 20 to residue 140;
• and
• an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:42 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 43 from residue 20 to residue 139.

A method for treating a solid tumor in a patient, the method comprising administering an antibody that binds human hepatocyte growth factor (HGF), wherein the antibody is selected from the group consisting of:

• an antibody comprising a light chain comprising SEQ ID NOs:
• 60, 70, and 80, and a heavy chain comprising SEQ ID NOs:
• 90, 100 and 110;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 61, 71, and 81, and a heavy chain comprising SEQ ID NOs:
• 91, 101, and 111;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 62, 72, and 82, and a heavy chain comprising SEQ ID NOs:
• 92, 102, and 112;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 63, 73, and 83, and a heavy chain comprising SEQ ID NOs:
• 93, 103, and 113;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 64, 74, and 84, and a heavy chain comprising SEQ ID NOs:
• 94, 104, and 114;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 65, 75, and 85, and a heavy chain comprising SEQ ID NOs:
• 95, 105, and 115;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 66, 76, and 86, and a heavy chain comprising SEQ ID NOs:
• 96, 106, and 116;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 67, 77, and 87, and a heavy chain comprising SEQ ID NOs:
• 97, 107, and 117;
• an antibody comprising a light chain comprising SEQ ID NOs:
• 68, 78, and 88, and a heavy chain comprising SEQ ID NOs:
• 98, 108, and 118;
• and
• an antibody comprising a light chain comprising SEQ ID NOs:
• 69, 79, and 89, and a heavy chain comprising SEQ ID NOs:
• 99, 109, and 119.